Breaking News

mAbs Retains Neutralizing Activity Against Omicron BA.x Variants

July 27, 2022 • 5:56 pm CDT
from Pixabay
(Coronavirus Today)

North Carolina-based  Brii Biosciences Limited announced today new live virus data confirming the amubarvimab/romlusevimab combination, a long-acting COVID-19 monoclonal antibody (mAb) therapy, retains neutralizing activity against the Omicron BA.4/5 and BA.2.12.1 SARS-CoV-2 subvariants.

Data from the live virus neutralization assay performed at a University of Maryland lab was certified by the U.S. NIH and NIAID and predicted that total serum concentrations of the amubarvimab/romlusevimab combination would remain greater than 170 times the level required for greater than 90% neutralization (Neut99: 0.94 μg/mL) against the live virus, 14 days post-dose. 

"As the COVID-19 pandemic continues to surge with evolving variants, these data further validate the durability and longevity of our long-acting amubarvimab/romlusevimab combination treatment and reinforce its position as a leading investigational monoclonal antibody therapy with the potential to retain activity against the most dominating strains that are circulating worldwide," commented David Margolis, M.D., MPH, Vice President and Head of Infectious Diseases Therapy Area at Brii Bio, in a press release issued on July 27, 2022.

"We're at a critical moment in the pandemic in which the new Omicron subvariants are more contagious, resulting in a sustained urgency for safe and effective treatment options."

"We look forward to continuing our discussions with global regulatory bodies as we work to advance this innovative combination therapy for COVID-19 patients in need around the world."

On December 8, 2021, the National Medical Products Administration of China approved this mAbs.

Currently, the U.S. FDA continues its evaluations.

Additional mAbs news is posted at this link.

Note: This announcement was manually curated for mobile readership.